SCHEMBL3958438

SCHEMBL3958438

CCOC(=O)c1ccc(Br)s1.[Zn]

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.57
HDAC4 P56524 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
GSK3B P49841 2/20 0.50
DAO P14920 1/20 0.50
HPGD P15428 3/20 0.49
RXFP1 Q9HBX9 3/20 0.49
TSHR P16473 3/20 0.49
POLB P06746 3/20 0.49
ALDH1A1 P00352 2/20 0.49
PPARG P37231 2/20 0.49
NCOA2 Q15596 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
CYP1A2 P05177 2/20 0.49
ESR1 P03372 2/20 0.49
MEN1 O00255 1/20 0.49
ALOX12 P18054 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL64687 0.98 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC6CES2
SCHEMBL7018973 0.85 HDAC3 (0.73) HDAC3HDAC4HDAC1HDAC6HPGD
SCHEMBL1164276 0.81 CES2 (0.60) HDAC3HDAC4HDAC1HDAC6CES2
SCHEMBL2659566 0.79 HDAC3 (0.62) HDAC3HDAC4HDAC1HDAC6DAO
SCHEMBL28383825 0.79 CES2 (0.52) HDAC3HDAC4HDAC1HDAC6CES2
SCHEMBL19224033 0.78 CES2 (0.47) HDAC3HDAC4HDAC1HDAC6CES2
SCHEMBL490430 0.78 GSK3B (0.54) CES2CES1GSK3BDAOHPGD
SCHEMBL2279695 0.78 CES2 (0.45) HDAC3HDAC4HDAC1HDAC6CES2
SCHEMBL7640681 0.78 HDAC3 (0.60) HDAC3HDAC4HDAC1HDAC6HPGD
SCHEMBL5068414 0.78 HDAC3 (0.65) HDAC3HDAC4HDAC1HDAC6DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2078003-B1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME (US) 2017-03-08 EP disclosed
US-9206142-B2 Anilinopiperazine derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2015-12-08 US disclosed
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC 2012-12-27 US disclosed
EP-2078003-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2009-07-15 EP disclosed
WO-2008054702-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MAPK15, CDK15, MAPKAPK5 HDAC3 1104/4885HDAC4 751/4885HDAC1 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.